Neurocrine Biosciences (NBIX) FCF Margin Growth (5y) (2016 - 2026)
Neurocrine Biosciences (NBIX) FCF Margin Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,082.00 |
| Mar 31, 2026 | -1,913.00 |
| Dec 31, 2025 | 1,435.00 |
| Sep 30, 2025 | 3,225.00 |
| Jun 30, 2025 | -2,317.00 |
| Mar 31, 2025 | -519.00 |
| Dec 31, 2024 | -1,173.00 |
| Sep 30, 2024 | -1,328.00 |
| Jun 30, 2024 | -2,254.00 |
| Mar 31, 2024 | 10,483.00 |
| Dec 31, 2023 | 275.00 |
| Sep 30, 2023 | -599.00 |
| Jun 30, 2023 | 2,514.00 |
| Mar 31, 2023 | 2,422.00 |
| Dec 31, 2022 | -231.00 |
| Sep 30, 2022 | 4,474.00 |
| Jun 30, 2022 | 143,997.00 |
| Mar 31, 2021 | 23,654.00 |
| Mar 31, 2020 | 10,803.00 |
| Dec 31, 2018 | 153,735.00 |